Recent Study: Cervical Cancer - Pipeline Review, H2 2013

Global Markets Direct's, 'Cervical Cancer - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Cervical Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cervical Cancer. Cervical Cancer - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

* A snapshot of the global therapeutic scenario for Cervical Cancer.
* A review of the Cervical Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
* Coverage of products based on various stages of development ranging from discovery till registration stages.
* A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
* Coverage of the Cervical Cancer pipeline on the basis of route of administration and molecule type.
* Key discontinued pipeline projects.
* Latest news and deals relating to the products.

Full Report Details at
- http://www.fastmr.com/prod/675198_cervical_cancer_pipeline_review_h2_2013.aspx?afid=301

Reasons to Get this Report

* Identify and understand important and diverse types of therapeutics under development for Cervical Cancer.
* Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
* Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
* Devise corrective measures for pipeline projects by understanding Cervical Cancer pipeline depth and focus of Indication therapeutics.
* Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
* Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Companies Mentioned in this Report: F. Hoffmann-La Roche Ltd., Helix BioPharma Corp., Sanofi-Aventis, GlaxoSmithKline plc, Gilead Sciences, Inc., Daiichi Sankyo Company, Ltd, Amorfix Life Sciences Ltd., MediGene AG, Nanotherapeutics, Inc., Novartis AG, Chong Kun Dang Pharmaceutical, Taiho Pharmaceutical Co., Ltd., Zeria Pharmaceutical Co Ltd, Genmab A/S, CEL-SCI Corporation, Advaxis, Inc., 3SBio Inc., Dendreon Corporation, Transgene SA, Antigen Express, Inc., Shantha Biotechnics Limited, Nutri Pharma ASA, Med Discovery SA, Priaxon AG, ApoImmune, Inc., PDS Biotechnology Corporation, Azaya Therapeutics, Inc., Genexine Co., Ltd., BT PHARMA, Genetic Immunity, LLC, Sirnaomics, Inc., Advanced Cancer Therapeutics, Xenova Group plc, Mycenax Biotech Inc., EyeGene, Inc., Vaccibody AS, ISA Pharmaceuticals B.V., Coridon Pty Ltd

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

You may also be interested in these related reports:

- Prostate Cancer - Pipeline Review, H2 2013
- Non-Small Cell Lung Cancer - Pipeline Review, H2 2013
- Colon Cancer - Pipeline Review, H2 2013
- Liver Cancer - Pipeline Review, H2 2013
- Metastatic Pancreatic Cancer - Pipeline Review, H2 2013